Kymera Therapeutics Inc
KYMR
Company Profile
Business description
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Contact
500 North Beacon Street
4th Floor
WatertownMA02472
USAT: +1 857 285-5300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
225
Stocks News & Analysis
stocks
Paying more for new customers is a troubling sign for ASX share
Shares fall close to 18% after reporting higher marketing expenses.
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
stocks
Berkshire Hathaway earnings: Cash hits record $373 billion on mostly solid results across the firm
We think Berkshire Hathaway stock is fairly valued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,117.10 | 303.40 | -3.22% |
| CAC 40 | 8,195.90 | 92.06 | 1.14% |
| DAX 40 | 24,209.42 | 418.77 | 1.76% |
| Dow JONES (US) | 48,750.59 | 249.32 | 0.51% |
| FTSE 100 | 10,571.06 | 209.05 | -1.94% |
| HKSE | 25,249.48 | 1,131.54 | -4.29% |
| NASDAQ | 22,824.15 | 307.46 | 1.37% |
| Nikkei 225 | 54,245.54 | 4,507.85 | -7.67% |
| NZX 50 Index | 13,531.12 | 139.59 | -1.02% |
| S&P 500 | 6,869.78 | 53.15 | 0.78% |
| S&P/ASX 200 | 8,901.20 | 280.50 | -3.05% |
| SSE Composite Index | 4,082.47 | 40.20 | -0.98% |